PCM
CRSP icon

Prelude Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Prelude Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,500
Closed -$219K – 1350
2023
Q4 		$219K Buy
+3,500
New +$193K 0.01% 905
2022
Q1 		– Sell
-4,200
Closed -$318K – 1895
2021
Q4 		$318K Buy
+4,200
New +$367K 0.01% 1284

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Prelude Capital Management's CRSP Position: Q2 2026 in Review

Prelude Capital Management opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 5,474 shares worth $299K. The stake represents 0.02% of the portfolio and ranks #779 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in CRSP as recently as Q4 2024.

Prelude Capital Management first reported a position in CRSP in Q4 2017 and has held it in 10 quarters since. The position peaked at $590K in Q4 2024. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Prelude Capital Management held 5,474 shares of CRISPR Therapeutics worth $299K as of Q2 2026.
  • CRISPR Therapeutics was a new Prelude Capital Management position in Q2 2026.
  • CRISPR Therapeutics made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #779 holding.
  • Prelude Capital Management first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 10 quarters since.
  • Prelude Capital Management's CRISPR Therapeutics position peaked at $590K in Q4 2024.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.